DX1002

N/A

Report date: 2024/09/11 14:41:07
NME

Base Information

Drug NameDX1002
Drug Alias NameDX-1002
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCadherin 5 inhibitorsTubulin inhibitors
TargetsCadherin 5Tubulin
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursLiver Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Anhao Pharmaceutical Technology Co LtdDongguan Daxin Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou Anhao Pharmaceutical Technology Co LtdDongguan Daxin Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursLiver Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A